Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma.
Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Wada N, Irie H, Hidaka T, Hashimoto A, Aiba S. Fujimura T, et al. Among authors: uchi h. Front Oncol. 2018 Nov 19;8:530. doi: 10.3389/fonc.2018.00530. eCollection 2018. Front Oncol. 2018. PMID: 30510916 Free PMC article.
Stromal expression of cathepsin K in squamous cell carcinoma.
Yan X, Takahara M, Xie L, Oda Y, Nakahara T, Uchi H, Takeuchi S, Tu Y, Moroi Y, Furue M. Yan X, et al. Among authors: uchi h. J Eur Acad Dermatol Venereol. 2011 Mar;25(3):362-5. doi: 10.1111/j.1468-3083.2010.03743.x. J Eur Acad Dermatol Venereol. 2011. PMID: 20524946
Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan.
Tsutsumida A, Takahashi A, Namikawa K, Yamazaki N, Uhara H, Teramoto Y, Takenouchi T, Fukushima S, Yokota K, Uehara J, Matsushita S, Shibayama Y, Hatta N, Masui Y, Uchi H, Fujisawa Y, Ogata D. Tsutsumida A, et al. Among authors: uchi h. Int J Clin Oncol. 2016 Aug;21(4):796-800. doi: 10.1007/s10147-015-0944-y. Epub 2016 Jan 13. Int J Clin Oncol. 2016. PMID: 26759315
Melanoma and Immune Checkpoint Inhibitors.
Furue M, Ito T, Wada N, Wada M, Kadono T, Uchi H. Furue M, et al. Among authors: uchi h. Curr Oncol Rep. 2018 Mar 23;20(3):29. doi: 10.1007/s11912-018-0676-z. Curr Oncol Rep. 2018. PMID: 29569208 Review.
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma.
Fujimura T, Sato Y, Tanita K, Lyu C, Kambayashi Y, Amagai R, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Uchi H, Yamamoto Y, Hata H, Funakoshi T, Nonomura Y, Tanaka R, Okuhira H, Wada N, Hashimoto A, Aiba S. Fujimura T, et al. Among authors: uchi h. Front Med (Lausanne). 2019 Apr 26;6:86. doi: 10.3389/fmed.2019.00086. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31080803 Free PMC article.
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.
Nakamura Y, Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, Nakamura Y, Fukushima S, Kiniwa Y, Takenouchi T, Uhara H, Kawai T, Hatta N, Funakoshi T, Teramoto Y, Otsuka A, Doi H, Ogata D, Matsushita S, Isei T, Hayashi T, Shibayama Y, Yamazaki N. Nakamura Y, et al. Among authors: uchi h. Ann Oncol. 2020 Sep;31(9):1198-1206. doi: 10.1016/j.annonc.2020.05.031. Epub 2020 Jun 6. Ann Oncol. 2020. PMID: 32522691 Free article.
247 results